Literature DB >> 22344247

Red blood cell folate concentrations and polyglutamate distribution in juvenile arthritis: predictors of folate variability.

Mara L Becker1, Leon van Haandel, Roger Gaedigk, Bradley Thomas, Mark F Hoeltzel, Andrew Lasky, Hongying Dai, John Stobaugh, James S Leeder.   

Abstract

OBJECTIVE: Methotrexate (MTX) has several enzymatic targets in the folate pathway. To better understand the variability in response to MTX, we characterized the interindividual variability of intracellular folate pools in children with juvenile arthritis (JA) and determined clinical and genetic contributors to this variability. STUDY
DESIGN: This exploratory single-center cross-sectional study evaluated 93 patients with JA not currently receiving MTX. Whole blood, plasma, and erythrocyte folate concentrations were determined after deconjugation and analyzed through reversed-phase separation and stable isotope dilution tandem mass spectrometry. Folate polyglutamates were measured in red blood cell lysates using an ion-pair reversed phase chromatography tandem mass spectrometry method.
RESULTS: Intracellular concentrations of 5-methyl-tetrahydrofolate (5-CH3-THF) and 5,10-methenyl-tetrahydrofolate varied approximately 20-fold and 80-fold, respectively. The polyglutamated forms of 5-CH3-THF as a percentage of total 5-CH3-THF (5-CH3-THFGlun) were also measured. Hierarchical clustering of 5-CH3-THFGlun revealed two groups, each with two distinct clusters. There was an inverse relationship between 5-CH3-THFGlun chain length and plasma 5-CH3-THF concentrations. A subgroup of patients with a historical intolerance to MTX had significantly lower cellular folate concentrations (P<0.0001). In univariate analyses, clinical variables including sex, age, and folate supplementation in addition to variations in MTHFR, MTR, and SLC25A32 were associated with differential intracellular folate redox concentrations. Multivariate analysis further supported the association of single nucleotide polymorphisms in SLC25A32, MTHFR, and MTR with variability in intracellular 5-CH3-THF and 5,10-methenyl-tetrahydrofolate concentrations, respectively.
CONCLUSION: Measurement of intracellular folate isoforms may contribute toward a better understanding of individual MTX effects in JA. Clinical variables in addition to genotypic differences beyond MTHFR may additionally explain differential intracellular folate concentrations and variable responses to MTX.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22344247     DOI: 10.1097/FPC.0b013e3283500202

Source DB:  PubMed          Journal:  Pharmacogenet Genomics        ISSN: 1744-6872            Impact factor:   2.089


  5 in total

Review 1.  Physiological and pathological roles of mitochondrial SLC25 carriers.

Authors:  Manuel Gutiérrez-Aguilar; Christopher P Baines
Journal:  Biochem J       Date:  2013-09-15       Impact factor: 3.857

2.  Folate depletion and increased glutamation in juvenile idiopathic arthritis patients treated with methotrexate.

Authors:  Ryan S Funk; Leon van Haandel; J Steven Leeder; Mara L Becker
Journal:  Arthritis Rheumatol       Date:  2014-12       Impact factor: 10.995

3.  Mitochondrial FAD shortage in SLC25A32 deficiency affects folate-mediated one-carbon metabolism.

Authors:  Min-Zhi Peng; Yong-Xian Shao; Xiu-Zhen Li; Kang-Di Zhang; Yan-Na Cai; Yun-Ting Lin; Min-Yan Jiang; Zong-Cai Liu; Xue-Ying Su; Wen Zhang; Xiao-Ling Jiang; Li Liu
Journal:  Cell Mol Life Sci       Date:  2022-06-21       Impact factor: 9.261

4.  Altered Folate Homeostasis in Children with Down Syndrome: A Potential Basis for Enhanced Methotrexate Toxicity.

Authors:  Ryan S Funk; Nasreen J Talib; Kanecia O Zimmerman; Leon van Haandel; Mara L Becker
Journal:  J Pediatr       Date:  2020-02-25       Impact factor: 4.406

5.  Methotrexate efficacy, but not its intolerance, is associated with the dose and route of administration.

Authors:  J Fráňová; Š Fingerhutová; K Kobrová; R Srp; D Němcová; J Hoza; M Uher; M Saifridová; L Linková; P Doležalová
Journal:  Pediatr Rheumatol Online J       Date:  2016-06-14       Impact factor: 3.054

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.